Merck and Eisai halt Keytruda-Lenvima trial in head and neck cancer due to disappointing results
TL;DR
Merck and Eisai have decided to halt a Phase III clinical trial studying the combination of Keytruda and Eisai's Lenvima in head and neck squamous cell carcinoma. The decision was made after an interim analysis showed that the combination did not improve overall survival compared to Keytruda and placebo in patients with PD-L1 expressing tumors. As the study was unlikely to meet its primary endpoint, the trial was stopped.
- Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer after disappointing interim results Endpoints News
- Another Keytruda-Lenvima ambition is dashed as Merck, Eisai end head and neck cancer trial FiercePharma
- Merck, Eisai discontinue late-stage study for combo cancer therapy Reuters
- LEAP-010 Trial Discontinued After OS Projection With Pembrolizumab/Lenvatinib in Metastatic HNSCC OncLive
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News